Boehringer Ingelheim’s SENVELGO gets EU marketing authorization for feline diabetes treatment
The European Commission has granted marketing authorization to Boehringer Ingelheim for SENVELGO (active ingredient: velagliflozin), a groundbreaking development in the treatment of feline diabetes across Europe. SENVELGO stands out as the world’s first once-daily liquid oral solution specifically designed to reduce hypoglycemia in cats with non-insulin-dependent diabetes mellitus. This innovative medication simplifies the management of […]